These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 36651583)
1. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification. Ammendola S; Broggi G; Barresi V Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583 [TBL] [Abstract][Full Text] [Related]
2. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723 [TBL] [Abstract][Full Text] [Related]
3. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
4. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590 [TBL] [Abstract][Full Text] [Related]
6. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted. Santosh V; Rao S Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130 [TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
8. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
9. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report. Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828 [TBL] [Abstract][Full Text] [Related]
10. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
12. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748 [TBL] [Abstract][Full Text] [Related]
13. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
16. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Banan R; Stichel D; Bleck A; Hong B; Lehmann U; Suwala A; Reinhardt A; Schrimpf D; Buslei R; Stadelmann C; Ehlert K; Prinz M; Acker T; Schittenhelm J; Kaul D; Schweizer L; Capper D; Harter PN; Etminan N; Jones DTW; Pfister SM; Herold-Mende C; Wick W; Sahm F; von Deimling A; Hartmann C; Reuss DE Acta Neuropathol; 2020 Oct; 140(4):569-581. PubMed ID: 32776277 [TBL] [Abstract][Full Text] [Related]
17. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
18. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification. Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
20. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]